Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: A cohort study

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Stiebel Kalish, Hadas ^a,b   Lotan, Itay ^a,b   Brody, Judith ^a,b   Chodick, Gabriel ^a   Bialer, Omer ^a,b   Marignier, Romain ^c   Bach, Michael ^d,e   Hellmann, Mark Andrew ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c HÔPITAL NEUROLOGIQUE   (France)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; AQP4 PROTEIN, HUMAN; AUTOANTIBODY;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; OPTIC NEURITIS; OUTCOME ASSESSMENT; RETINAL NERVE FIBER LAYER THICKNESS; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; VISUAL ACUITY; VISUAL FIELD DEFECT; YOUNG ADULT; BIOSYNTHESIS; DIAGNOSTIC IMAGING; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MYELINATED NERVE; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; VISUAL FIELD;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; CHILD; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NERVE FIBERS, MYELINATED; OPTIC NERVE; OPTIC NEURITIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VISUAL FIELDS;

EID: 85010934359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170847     Document Type: Article

References (24)

1. Boudreault K, Durand ML, Rizzo JF 3rd. Investigation-Directed Approach to Inflammatory Optic Neuropathies. Semin Ophthalmol. 2016; 31: 117-130. doi: 10.3109/08820538.2015.1114835 PMID: 26959137
2. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85: 177-189. doi: 10.1212/WNL.0000000000001729 PMID: 26092914
3. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014; 82: 474-481. doi: 10.1212/WNL.0000000000000101 PMID: 24415568
4. Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry. 2016.
5. Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2015.
6. Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014; 1: e40. doi: 10.1212/NXI.0000000000000040 PMID: 25364774
7. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012; 79: 1273-1277. doi: 10.1212/WNL.0b013e31826aac4e PMID: 22914827
8. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016; 79: 206-216. doi: 10.1002/ana.24554 PMID: 26537743
9. Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010; 9: 921-932. doi: 10.1016/S1474-4422(10)70168-X PMID: 20723847
10. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015.
11. Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012; 7: e34823. doi: 10.1371/journal.pone.0034823 PMID: 22536333
12. Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016; 86: 2303-2309. doi: 10.1212/WNL.0000000000002774 PMID: 27225223
13. Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories "hand motion" and "counting fingers" using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009; 247: 137-142. doi: 10.1007/s00417-008-0926-0 PMID: 18766368
14. Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006; 47: 1236-1240. doi: 10.1167/iovs.05-0981 PMID: 16505064
15. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016; 87: 446-448. doi: 10.1136/jnnp-2014-310206 PMID: 25749692
16. Wang JJ, Jaunmuktane Z, Mummery C, Brandner S, Leary S, Trip SA. Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology. 2016.
17. Hokari M, Yokoseki A, Arakawa M, Saji E, Yanagawa K, Yanagimura F, et al. Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol. 2016; 79: 605-624. doi: 10.1002/ana.24608 PMID: 26836302
18. Marignier R, Ruiz A, Cavagna S, Nicole A, Watrin C, Touret M, et al. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. J Neuroinflammation. 2016; 13: 111. doi: 10.1186/s12974-016-0577-8 PMID: 27193196
19. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-2112. doi: 10.1016/S0140-6736(04)17551-X PMID: 15589308
20. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016; 13: 280. doi: 10.1186/s12974-016-0718-0 PMID: 27793206
21. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016; 13: 282. doi: 10.1186/s12974-016-0720-6 PMID: 27802824
22. Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Cobo Calvo A, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015; 21: 866-874. doi: 10.1177/1352458514555785 PMID: 25344373
23. Willison HJ, Linington C. Antibodies to MOG in NMO: a seasoned veteran finds a new role. Neurology. 2012; 79: 1198-1199. doi: 10.1212/WNL.0b013e31826aadaf PMID: 22914829
24. Fan Q, Teo YY, Saw SM. Application of advanced statistics in ophthalmology. Invest Ophthalmol Vis Sci. 2011; 52: 6059-6065. doi: 10.1167/iovs.10-7108 PMID: 21807933